CarThera raises €9m to tackle the blood-brain barrierFrench company CarThera has raised €9 million in its Series B funding round to help it develop ultrasound-based Share XCarThera raises €9m to tackle the blood-brain barrierhttps://pharmaphorum.com/news/carthera-raises-e9m-to-tackle-the-blood-brain-barrier/
Ipsen warns over medicine supplies amid Brexit uncertaintyFrance’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma Share XIpsen warns over medicine supplies amid Brexit uncertaintyhttps://pharmaphorum.com/news/ipsen-warns-over-medicine-supplies-amid-brexit-uncertainty/
WuXi AppTec eyes acquisitions after $1bn Hong Kong IPOChinese biotech WuXi AppTec has completed its listing on Hong Kong’s HKEX, raising $967m just months after making Share XWuXi AppTec eyes acquisitions after $1bn Hong Kong IPOhttps://pharmaphorum.com/news/wuxi-apptec-eyes-acquisitions-after-1bn-hong-kong-ipo/
NICE rejects Alnylam and Akcea’s amyloidosis drugsNICE has rejected two pioneering drugs for the rare inherited condition, hereditary transthyretin-related amyloidosis (hATTR) in first draft Share XNICE rejects Alnylam and Akcea’s amyloidosis drugshttps://pharmaphorum.com/news/nice-rejects-alnylam-and-akceas-amyloidosis-drugs/
J&J’s Tremfya outperforms Novartis’ Cosentyx in psoriasisA large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had Share XJ&J’s Tremfya outperforms Novartis’ Cosentyx in psoriasishttps://pharmaphorum.com/news/jjs-tremfya-outperforms-novartis-cosentyx-in-psoriasis/
AZ begins liver cancer immunotherapy tie-up with AVEOAstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in Share XAZ begins liver cancer immunotherapy tie-up with AVEOhttps://pharmaphorum.com/news/az-begins-liver-cancer-immunotherapy-tie-up-with-aveo/
Garmin to develop wearables for clinical trials with ActiGraphTech-giant Garmin is stepping into the medical wearables space through a new collaboration with ActiGraph. The partnership will Share XGarmin to develop wearables for clinical trials with ActiGraphhttps://pharmaphorum.com/news/garmin-wearables-clinical-trials-actigraph/
Neurocrine slumps as Tourette’s drug fails clinical trialShares in Neurocrine Biosciences slumped by as much as a fifth after a much-anticipated trial in Tourette’s syndrome missed Share XNeurocrine slumps as Tourette’s drug fails clinical trialhttps://pharmaphorum.com/news/neurocrine-slumps-as-tourettes-drug-fails-clinical-trial/
Novo begins R&D tie-up with AI biotech e-TherapeuticsNovo Nordisk has signed a deal with UK biotech e-Therapeutics to use its AI-based drug discovery technology to Share XNovo begins R&D tie-up with AI biotech e-Therapeuticshttps://pharmaphorum.com/news/novo-begins-rd-tie-up-with-ai-biotech-e-therapeutics/
Axovant axes neuroscience drug, focuses on gene therapiesSwiss biotech Axovant started the year badly, dropping its Alzheimer’s drug intepirdine after it failed in a trial, Share XAxovant axes neuroscience drug, focuses on gene therapieshttps://pharmaphorum.com/news/axovant-axes-neuroscience-drug-focuses-on-gene-therapies/
Shinichi Tamura re-takes CEO role at SoseiSosei has announced that its founder and former CEO Shinichi Tamura will be re-taking the position of CEO Share XShinichi Tamura re-takes CEO role at Soseihttps://pharmaphorum.com/news/shinichi-tamura-re-takes-ceo-role-sosei/
Eisai, Takeda and GARDP hunt for new antibioticsThe not-for-profit Global Antibiotic Research and Development Partnership has joined forces with Eisai and Takeda to search for Share XEisai, Takeda and GARDP hunt for new antibioticshttps://pharmaphorum.com/news/eisai-takeda-and-gardp-hunt-for-new-antibiotics/
FDA clears Pear/Sandoz app for opioid use disorderA second mobile app developed by Pear Therapeutics to help opioid use disorder patients who have a more Share XFDA clears Pear/Sandoz app for opioid use disorderhttps://pharmaphorum.com/news/fda-clears-pear-sandoz-app-for-opioid-use-disorder/
Clark Health Communications forms alliance with EggLondon-based consultancy Clark Health Communications is partnering with digital solutions agency Egg in a collaboration that will see Share XClark Health Communications forms alliance with Egghttps://pharmaphorum.com/news/clark-health-communications-egg-digital/
NICE reveals new standards for digital techNICE has published new standards setting out the requirements needed to develop digital health technologies for the NHS Share XNICE reveals new standards for digital techhttps://pharmaphorum.com/news/nice-reveals-new-standards-for-digital-tech/
Generics firms the ‘biggest cartel in US history’ – reportUS authorities looking into price fixing in the generics industry are now investigating 16 companies and the price Share XGenerics firms the ‘biggest cartel in US history’ – reporthttps://pharmaphorum.com/news/generics-firms-the-biggest-cartel-in-us-history-report/
Akorn searches for new CEO after failed Fresenius mergerUS generics firm Akorn is searching for a new CEO in the wake of a failed merger with Share XAkorn searches for new CEO after failed Fresenius mergerhttps://pharmaphorum.com/news/akorn-searches-for-new-ceo-after-failed-fresenius-merger/
Certain brain tumours could respond to immunotherapySome brain tumours may respond to immunotherapy after all, according to a new study. So far, brain tumours Share XCertain brain tumours could respond to immunotherapyhttps://pharmaphorum.com/news/certain-brain-tumours-could-respond-to-immunotherapy/
Genentech develop Antibiotic with potential to lead to new class of Antibiotics Share XGenentech develop Antibiotic with potential to lead to new class of Antibioticshttps://pharmaphorum.com/partner-content/genentech-develop-antibiotic-with-potential-to-lead-to-new-class-of-antibiotics/
Hear from PFS industry leaders from big pharma & government bodies Share XHear from PFS industry leaders from big pharma & government bodieshttps://pharmaphorum.com/partner-content/hear-from-pfs-industry-leaders-from-big-pharma-government-bodies/
Invite from James Drinkwater Chairing 2nd Annual Pharmaceutical Microbiology East Coast Share XInvite from James Drinkwater Chairing 2nd Annual Pharmaceutical Microbiology East Coasthttps://pharmaphorum.com/partner-content/invite-from-james-drinkwater-chairing-2nd-annual-pharmaceutical-microbiology-east-coast/
The Strategies to Reach Out and Engage with Your Customers Share XThe Strategies to Reach Out and Engage with Your Customershttps://pharmaphorum.com/partner-content/the-strategies-to-reach-out-and-engage-with-your-customers/
pharmaphorum welcomes George Underwood to its editorial helm Share Xpharmaphorum welcomes George Underwood to its editorial helmhttps://pharmaphorum.com/news/pharmaphorum-welcomes-george-underwood-to-its-editorial-helm/
STEM Healthcare appoints Jason McKenna as CEO Share XSTEM Healthcare appoints Jason McKenna as CEOhttps://pharmaphorum.com/partner-content/stem-healthcare-appoints-jason-mckenna-as-ceo/
